BioStem (BSEM) Director Mark Glickman Converts 7,671 RSUs

What Happened

• Mark A. Glickman, a director of BioStem Technologies, converted/exercised 7,671 derivative units on August 27, 2026 (reported on Form 4 filed 2026-08-28). The filing shows 7,671 shares acquired and the same 7,671 shares disposed, both at $0.00, with total reported cash value $0. This transaction reflects a conversion/settlement event for restricted stock units that vested on August 27, 2026, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-27; Form 4 filed: 2026-08-28 (timely filing).
• Transaction code: M (exercise or conversion of a derivative security).
• Shares acquired: 7,671 @ $0.00; Shares disposed: 7,671 @ $0.00.
• Footnotes: F1 — each restricted stock unit (RSU) equals a contingent right to receive one share; F2 — these RSUs vested on Aug 27, 2026.
• Shares owned after the transaction: not specified in this filing.
• Exhibit/remark: Exhibit 24 — Power of Attorney.

Context

• The filing reports both acquisition and disposition of the same shares at $0.00, which typically indicates conversion/settlement of vested RSUs (often involving transfer or withholding for tax/settlement) rather than an open-market sale. This is a vesting/settlement event and not a cash purchase; such events are common compensation-related transactions and do not necessarily signal a change in insider sentiment. For exact post-transaction holdings or tax/withholding details, review the company's other filings or subsequent amendments.